Proteomedix
Schlieren
About Proteomedix
Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $21.3M
- Funding stage: M&A
- Last round: Debt Financing (Sep 2021)
- Website: proteomedix.com
- Phone: 0041 44 733 40 90
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/proteomedix-67446 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.